Latest Conference Articles

Avacopan Achieves Sustained Remission in Real World Severe ANCA Vasculitis Data, With Naomi Patel, MD

ByNaomi Patel, MD

March 5th 2026

Patel shared findings from a retrospective cohort study in people with GPA or MPA at RWCS 2026.

Addressing the Pediatric Rheumatology Workforce Crisis, with Susan Shenoi, MD

BySusan Shenoi, MD, MS

February 25th 2026

Shenoi discussed how the rheumatology field continues to adapt to workforce shortages.

Integrating AI Into Everyday Rheumatology Practice, with Alvin Wells, MD, PhD, and Orrin Troum, MD

ByOrrin M. Troum, MD,Alvin Wells, MD, PhD

February 24th 2026

Troum and Wells discussed how AI tools help clinicians in their practice.

From Clinical Trials to Clinic: Making Sense of Rheumatology Metrics, with Roy Fleischmann, MD

ByRoy M. Fleischmann, MD

February 23rd 2026

Flesichmann shared highlights from his talk at RWCS 2026.

Precision Medicine and the Pursuit of Remission in RA and PsA, with Arthur Kavanaugh, MD

ByArthur Kavanaugh, MD

February 20th 2026

Kavanaugh discussed how far the field is to true precision medicine at RWCS 2026.

Improving Recognition and Outcomes in Vasculitis, with Anisha Dua, MD

ByAnisha B. Dua, MD, MPH

February 19th 2026

Dua discussed the vasculitis field's progression to "precision medicine" and more.

Advancing Research and Access in Modern Osteoporosis Care, with Gina Woods, MD

ByGina Woods, MD

February 19th 2026

Woods discussed integrating exercise into osteoporosis care and high priority research questions.

GLP-1 RAs and Beyond: Integrating Metabolic Health into PsA and RA Care, with Eric Ruderman, MD

GLP-1s and Beyond: Integrating Metabolic Health into PsA and RA Care, with Eric Ruderman, MD

ByEric M. Ruderman, MD

February 18th 2026

Ruderman emphasized growing interest in metabolic health with the rise of GLP-1 RA usage.

What Mattered Most in 2025 for RA and PsA, with Arthur Kavanaugh, MD

ByArthur Kavanaugh, MD

February 17th 2026

Kavanaugh discussed priorities in the disease fields in the last year of research.

Optimizing Osteoporosis Prevention and Therapy Selection, with Gina Woods, MD

ByGina Woods, MD

February 14th 2026

Woods discussed navigating conversations with patients about preventive therapy and the benefit-risk profile.

Do Updated Vasculitis Classification Criteria Change Practice, With Anisha Dua, MD

ByAnisha B. Dua, MD, MPH

February 14th 2026

Dua discussed the latest guideline updates, the most recent since 1990.

Treatment Choices and Sequencing in PsA, With Eric Ruderman, MD

ByEric M. Ruderman, MD

February 13th 2026

Ruderman discussed recent research examining treatment choices after failure.

Integrating Muscle, Nutrition, and Function into Bone Care, with Gina Woods, MD

ByGina Woods, MD

February 13th 2026

Woods shared extra-rheumatological considerations to keep in mind when managing patients' bone health.

Improving Diagnostic Precision and Long-Term Control in Large Vessel Vasculitis, with Anisha Dua, MD, MPH

ByAnisha B. Dua, MD, MPH

February 12th 2026

Dua emphasized exciting progress in the field for giant cell and arteritis and Takeyasu arteritis.

Difficult-to-Treat Disease in PsA and axSpA: Lessons from 2025, with Eric Ruderman, MD

ByEric M. Ruderman, MD

February 11th 2026

Ruderman discussed the topics of his year in review talks at RWCS 2026.

What to Expect at RWCS 2026

ByVictoria Johnson

February 10th 2026

This preview of RWCS 2026 highlights some of the sessions and interviews to look forward to.

Deucravacitinib, Zasocitinib Validate TYK2 Inhibition in PsA, With Philip Mease, MD

ByPhilip J. Mease, MD

January 21st 2026

Mease discussed the latest updates on deucravacitinib and zasocitinib at ACR Convergence 2025.

The Expanding Lupus Pipeline: Obinutuzumab and What's Next, With Rosalind Ramsey-Goldman, MD

ByRosalind Ramsey-Goldman, MD

January 13th 2026

Ramsey-Goldman discussed how the lupus field has shifted from her earlier career.

Polygenic Risk Scores Linked to Specific SLE Manifestations, With Matthew Dapas, PhD

ByMatthew Dapas, PhD

December 4th 2025

ACR 2025 research shows polygenic risk scores correlate with specific SLE phenotypes, highlighting potential applications for clinical risk assessment.

Matthew Dapas, PhD I Credit: Feinberg School of Medicine

Polygenic Risk Scores Reveal Genetic Drivers of Lupus Heterogeneity, With Matthew Dapas, PhD

ByMatthew Dapas, PhD

November 24th 2025

At ACR 2025, Dapas discusses how polygenic risk scores link genetic risk to SLICC criteria, advancing precision medicine in systemic lupus erythematosus.

Fatigue, Pain, Daily Function: DZP’s Patient-Centered Impact in SLE, with Rosalind Ramsey-Goldman, MD

ByRosalind Ramsey-Goldman, MD

November 18th 2025

Ramsey-Goldman emphasized the importance of QoL in lupus, looking beyond disease scores.

Proof of Concept: Targeting Mitochondrial Dysfunction in SLE With NAC, with Rosalind Ramsey-Goldman, MD

ByRosalind Ramsey-Goldman, MD

November 18th 2025

Ramsey-Goldman discussed the potential of NAC for treating systemic lupus erythematosus.

Adipose-Derived MSCs Show Promise as Nonsurgical Option for Knee OA, With Moshiur Rahman Khasru, MBBS, MSc

ByMoshiur Rahman Khasru, MBBS, MSc

November 14th 2025

Khasru discussed the potential of adMSCs to improve outcomes in knee osteoarthritis.

Bringing Attention to the Cognitive Impacts of SLE, With Carla Marie Cuda, PhD

ByCarla Marie Cuda, PhD

November 6th 2025

Cuda also discussed further research she'd like to do with cognition and SLE.

Incorporating Cognitive QoL Into Lupus Trials, With Carla Marie Cuda, PhD

ByCarla Marie Cuda, PhD

November 6th 2025

Cuda discussed the potential of the NIH toolbox to easily assess cognitive effects in clinical trials.

Achieving “State Zero”: New Data on Bimekizumab, Other IL-17is, Transform PsA Treatment Goals, with Philip Mease, MD

ByPhilip J. Mease, MD

October 30th 2025

Mease discussed the latest updates on bimekizumab, sonelokimab, and izokibep at ACR Convergence 2025.

Telitacicept Improves Sjögren Symptoms Over Placebo in Phase 3 Trial

ByVictoria Johnson

October 25th 2025

Telitacicept significantly alleviates Sjögren disease symptoms over 48 weeks, outperforming placebo with a favorable safety profile in a phase 3 trial.

Risankizumab Maintains PsA Disease Control Through 5 Years in KEEPsAKE 1 & 2 Trials

ByLana Pine

October 25th 2025

In long-term follow-up of KEEPsAKE 1 and 2, risankizumab maintained joint, skin, pain, and axial responses in patients with PsA through 244 weeks.

Telitacicept Significantly Improves Lupus Response Rates Above SOC Alone

ByVictoria Johnson

October 16th 2025

However, a notable higher rate of treatment-related adverse events warrants caution.

Sonelokimab Demonstrates Psoriatic Arthritis Improvements Over Placebo

ByVictoria Johnson

October 10th 2025

Sonelokimab meets ACR50 primary endpoint in a phase 2 trial.

Latest Conference Articles

Avacopan Achieves Sustained Remission in Real World Severe ANCA Vasculitis Data, With Naomi Patel, MD

Addressing the Pediatric Rheumatology Workforce Crisis, with Susan Shenoi, MD

Integrating AI Into Everyday Rheumatology Practice, with Alvin Wells, MD, PhD, and Orrin Troum, MD

From Clinical Trials to Clinic: Making Sense of Rheumatology Metrics, with Roy Fleischmann, MD

Precision Medicine and the Pursuit of Remission in RA and PsA, with Arthur Kavanaugh, MD

Improving Recognition and Outcomes in Vasculitis, with Anisha Dua, MD

Advancing Research and Access in Modern Osteoporosis Care, with Gina Woods, MD

GLP-1s and Beyond: Integrating Metabolic Health into PsA and RA Care, with Eric Ruderman, MD

What Mattered Most in 2025 for RA and PsA, with Arthur Kavanaugh, MD

Optimizing Osteoporosis Prevention and Therapy Selection, with Gina Woods, MD

Do Updated Vasculitis Classification Criteria Change Practice, With Anisha Dua, MD

Treatment Choices and Sequencing in PsA, With Eric Ruderman, MD

Integrating Muscle, Nutrition, and Function into Bone Care, with Gina Woods, MD

Improving Diagnostic Precision and Long-Term Control in Large Vessel Vasculitis, with Anisha Dua, MD, MPH

Difficult-to-Treat Disease in PsA and axSpA: Lessons from 2025, with Eric Ruderman, MD

What to Expect at RWCS 2026

Deucravacitinib, Zasocitinib Validate TYK2 Inhibition in PsA, With Philip Mease, MD

The Expanding Lupus Pipeline: Obinutuzumab and What's Next, With Rosalind Ramsey-Goldman, MD

Polygenic Risk Scores Linked to Specific SLE Manifestations, With Matthew Dapas, PhD

Polygenic Risk Scores Reveal Genetic Drivers of Lupus Heterogeneity, With Matthew Dapas, PhD

Fatigue, Pain, Daily Function: DZP’s Patient-Centered Impact in SLE, with Rosalind Ramsey-Goldman, MD

Proof of Concept: Targeting Mitochondrial Dysfunction in SLE With NAC, with Rosalind Ramsey-Goldman, MD

Adipose-Derived MSCs Show Promise as Nonsurgical Option for Knee OA, With Moshiur Rahman Khasru, MBBS, MSc

Bringing Attention to the Cognitive Impacts of SLE, With Carla Marie Cuda, PhD

Incorporating Cognitive QoL Into Lupus Trials, With Carla Marie Cuda, PhD

Achieving “State Zero”: New Data on Bimekizumab, Other IL-17is, Transform PsA Treatment Goals, with Philip Mease, MD

Telitacicept Improves Sjögren Symptoms Over Placebo in Phase 3 Trial

Risankizumab Maintains PsA Disease Control Through 5 Years in KEEPsAKE 1 & 2 Trials

Telitacicept Significantly Improves Lupus Response Rates Above SOC Alone

Sonelokimab Demonstrates Psoriatic Arthritis Improvements Over Placebo

Trending on Rheumatology Live

Enpatoran Gets FDA Breakthrough Therapy Designation for Lupus With Cutaneous Manifestations